Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study.

Rorie DA, Rogers A, Mackenzie IS, Ford I, Webb DJ, Willams B, Brown M, Poulter N, Findlay E, Saywood W, MacDonald TM.

BMJ Open. 2016 Feb 9;6(2):e010313. doi: 10.1136/bmjopen-2015-010313.

2.

Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.

Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, Mackenzie IS, Padmanabhan S, MacDonald TM; British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group.

Lancet Diabetes Endocrinol. 2016 Feb;4(2):136-47. doi: 10.1016/S2213-8587(15)00377-0. Epub 2015 Oct 18.

3.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group.

Lancet. 2015 Nov 21;386(10008):2059-68. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20.

4.

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension.

Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I, Brown MJ.

BMJ Open. 2015 Aug 7;5(8):e008951. doi: 10.1136/bmjopen-2015-008951.

5.

Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension.

Brown MJ, Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I.

BMJ Open. 2015 Aug 7;5(8):e008086. doi: 10.1136/bmjopen-2015-008086.

6.

Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial.

MacDonald TM, Williams B, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Mackenzie IS, Salsbury J, Morant S, Ford I, Brown MJ.

BMJ Open. 2015 Aug 7;5(8):e007645. doi: 10.1136/bmjopen-2015-007645.

7.

Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?

Jennings CG, MacDonald TM, Wei L, Brown MJ, McConnachie L, Mackenzie IS.

Trials. 2015 Mar 7;16:80. doi: 10.1186/s13063-015-0582-8.

8.

Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis.

Flynn RW, MacDonald TM, Hapca A, MacKenzie IS, Schembri S.

Respir Res. 2014 Nov 19;15:141. doi: 10.1186/s12931-014-0141-y.

9.

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.

MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, Hallas J, Hawkey CJ, Ralston S, Walters M, Webster J, McMurray J, Perez Ruiz F, Jennings CG; Members of the FAST Study Group.

BMJ Open. 2014 Jul 10;4(7):e005354. doi: 10.1136/bmjopen-2014-005354.

10.

Renal artery stenosis-when to screen, what to stent?

Jennings CG, Houston JG, Severn A, Bell S, Mackenzie IS, Macdonald TM.

Curr Atheroscler Rep. 2014 Jun;16(6):416. doi: 10.1007/s11883-014-0416-2. Review.

11.

Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study.

George J, Majeed W, Mackenzie IS, Macdonald TM, Wei L.

BMJ. 2013 Nov 26;347:f6954. doi: 10.1136/bmj.f6954.

12.

Effectiveness of newspaper advertising for patient recruitment into a clinical trial.

Hapca A, Jennings CG, Wei L, Wilson A, MacDonald TM, Mackenzie IS.

Br J Clin Pharmacol. 2014 Jun;77(6):1064-72. doi: 10.1111/bcp.12262.

13.

Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database.

Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J.

J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):76-84. doi: 10.1136/jnnp-2013-305450. Epub 2013 Sep 19.

14.

Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function.

Wei L, MacDonald TM, Jennings C, Sheng X, Flynn RW, Murphy MJ.

Kidney Int. 2013 Jul;84(1):174-8. doi: 10.1038/ki.2013.76. Epub 2013 Mar 13.

16.

The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population.

Sheng X, Murphy MJ, MacDonald TM, Wei L.

BMC Public Health. 2012 Aug 30;12:712. doi: 10.1186/1471-2458-12-712.

17.

Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.

Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L.

BMJ. 2012 Jul 13;345:e4447. doi: 10.1136/bmj.e4447.

18.

Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis.

Mackenzie IS, Wei L, Macdonald TM.

Eur J Clin Pharmacol. 2013 Feb;69(2):133-41. doi: 10.1007/s00228-012-1335-1. Epub 2012 Jun 26.

19.

Pioglitazone and bladder cancer: a propensity score matched cohort study.

Wei L, MacDonald TM, Mackenzie IS.

Br J Clin Pharmacol. 2013 Jan;75(1):254-9. doi: 10.1111/j.1365-2125.2012.04325.x.

20.

Effectiveness of statins in chronic kidney disease.

Sheng X, Murphy MJ, Macdonald TM, Wei L.

QJM. 2012 Jul;105(7):641-8. doi: 10.1093/qjmed/hcs031. Epub 2012 Feb 29.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk